

# Improvements In Quality of Life, Health Utility, Cost, and Return to Work for Lymphoma Patients After Chimeric Antigen Receptor T Cell therapy in a Real-World Setting

Project duration: 2025-3-1 to 2028-3-31

Targeted cancer type:

## Blood cancers

This study aims to generate real-world evidence on patient quality of life, financial burdens, and cost-effectiveness of CAR T cell therapy in Canada to inform policy and decision-making.

Project value:

## \$235,000

BioCanRx Contribution:

## \$200,000

Biotherapeutic:

## Adoptive Cell Therapy

Key Investigators:

Project Lead:

**Dr. Kelvin Chan**



**Dr. William Wong**



**Dr. Anca Prica**



**Dr. Pierre Villeneuve**



**Dr. Amaris Balitsky**



**Dr. Stuart Peacock**



# 1

Partner



## About the project:

Chimeric antigen receptor (CAR)T-cells have transformed oncology treatment, offering the potential to cure certain end-stage cancers including lymphoma. While shown to be effective, the extremely high cost of CAR T-cell therapies (>\$450,000 USD), together with a substantial use of health care resources, will make this therapy among the most challenging drug reimbursement problems in Canada in the 2020s. CADTH (now CDA), in their funding recommendation, called for “the collection

of standardized outcomes data...to generate real-world evidence, for consideration in future reassessments”. A critical missing, part of the evidence required to formulate CAR T-cell treatment policy relates to patient perspectives. Data are missing information on: i) whether treatment improves health related quality of life (HRQOL); and ii) patient borne costs of the therapy, including lost work productivity. This team's goal is to generate evidence to determine the burden of the disease related to CAR T-cell therapy

by : 1) Evaluating the impact of CAR T-cell therapy on HRQOL in eligible patients with lymphoma; 2) Obtaining estimates of costs associated with CAR T-cell therapy and 3) Evaluating the cost-effectiveness of CAR T-cell therapy.

Insights from this study will have direct relevance to and will enable the cost-effectiveness analyses and decision making of CAR T-Cell therapies with a Canadian context.



**Partner:**  
Ontario Institute for Cancer Research

**Total Pledged Partner Contributions: \$35,000**  
**Total Pledged Matched Contributions: \$35,000**

**Key Deliverables**

1. Completed analysis about how CAR T cell therapy impacts HRQOL in patients with DLBCL
2. Completed analysis on the financial burden experienced by DLBCL patients receiving CAR T cell therapy
3. Real-world cost effective analysis of CAR T cell therapy in DLBCL patients

The power to kill cancer lies within us. Let’s tell our bodies how.